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Marine biodiversity is recognized by a wide and unique array of fascinating structures. The
complex associations of marine microorganisms, especially with sponges, bryozoans,
and tunicates, make it extremely difficult to define the biosynthetic source of marine
natural products or to deduce their ecological significance. Marine sponges and tunicates
are important source of novel compounds for drug discovery and development. Majority
of these compounds are nitrogen containing and belong to non-ribosomal peptide
(NRPs) or mixed polyketide–NRP natural products. Several of these peptides are
currently under trial for developing new drugs against various disease areas, including
inflammatory, cancer, neurodegenerative disorders, and infectious disease. This review
features pharmacologically active NRPs from marine sponge and tunicates based on
their biological activities.
Keywords: marine ecosystem, sponge, tunicates, marine natural products, non-ribosomal peptides,
pharmacology
INTRODUCTION
Nature provides a wide and structurally diverse array of active biomolecules that have proved vital
for the development of novel pharmaceuticals. The marine world, covering more than 70% of the
Earth’s surface, is the home of tremendous biodiversity. Due to very diverse oceanic environments,
marine organisms have developed the capacity to produce unique compounds (Steele, 1985;
Mehbub et al., 2014). This rich and unprecedented chemo diversity of marine natural products
provides an unlimited resource of novel biomolecules in the field of drug development. The
importance of marine metabolites in current drug research is driven by the fact, that during
1981–2002, around half of US FDA-approved drugs consisted of either marine metabolites or
their synthetic analogs (Vinothkumar and Parameswaran, 2013). Interestingly, the majority of
these natural products involved in clinical or preclinical trials are produced by invertebrates, that
is, sponges, tunicates, bryozoans, or molluscs. Sixty per cent of these natural products belong
to non-ribosomal peptide (NRP) families, which are biosynthesized by poly-functional mega-
synthases called NRP synthetases (NRPSs) (Finking and Marahiel, 2004; Mehbub et al., 2014).
The excellent binding properties, low off-target toxicity, and high stability of NRPs make them a
promising molecule for development of new therapeutics. Currently, only a handful of NRPs are
used as drug (Table 1).
Marine sponges (Phylum porifera) represent the most primitive multicellular animals,
with origins dating back to the Precambrian era (Hentschel et al., 2002). There are about
9000 reported species of sponges and (perhaps twice as many unreported species) available
in the ocean (Brusca et al., 1990; Wörheide et al., 2005). These have been broadly
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categorized in 3 classes : Calcarea (5 orders and 24 families),
Demospongiae (15 orders and 92 families), and Hexactinellida
(6 orders and 20 families). Till date, more than 5300
different natural products have been isolated from marine
sponges, and each year more than 200 additional new
metabolites are being discovered (Laport et al., 2009; Mehbub
et al., 2014). There are several sponge derived metabolites
currently available in market and many in clinical studies
(Table 2).
It is proposed that some of the bioactive compounds
isolated from sponges are produced by functional enzyme
clusters originated from the sponges and their associated
microorganisms (Laport et al., 2009; Thomas et al., 2010). It
has been observed that bacterial phyla such as Proteobacteria,
Nitrospira, Cyanobacteria, Bacteriodetes, Actinobacteria,
Chloroflexi, Planctomycetes, Acidobacteria, Poribacteria, and
Verrucomicrobia besides members of the domain Archaea
are most sponge-associated bacterial community (Hentschel
TABLE 1 | NRPs-based drugs in market.
Compound Biosynthetic class of agent Source Disease/molecular target Reference
Polymyxin B Polypeptides Bacillus polymyxa Antibiotic/Alters bacterial outer membrane Paulus and Gray, 1964
Pristinamycin Depsipeptide Streptomyces. pristinaespiralis Antibiotic/protein synthesis inhibitor de Crécy-Lagard et al., 1997
Gramicidin Linear pentadecapeptide Bacillus bovis Antibiotic/Alters bacterial outer membrane Kleinkauf and von Döhren, 1995
Bacitracin Cyclic peptide Bacillus subtilis Antibiotic/dephosphorylation of
C55-isoprenyl pyrophosphate
Johnson et al., 1945
Capreomycin Cyclic peptide Streptomyces capreolus Antibiotic/protein synthesis inhibitor Stark et al., 1962
Teicoplanin Glycopeptide Actinoplanes teichomyceticus Antibiotic/inhibit cell wall synthesis Somma et al., 1984
Vancomycin Glycopeptide Amycolatopsis orientalis Antibiotic/inhibit cell wall synthesis Van Wageningen et al., 1998
Cephalosporin C β-lactam Acremonium sp. Antibiotic/Alters bacterial outer membrane Abraham and Newton, 1961
Oritavancin – Semi synthetic Antibiotic/disrupts the cell membrane Domenech et al., 2009
Bleomycin Hybrid peptide Streptomyces verticillus Antibiotic/inhibition of DNA synthesis Umezawa et al., 1966
Daptomycin Lipopeptide Streptomyces roseosporus Antibiotic/disrupts the cell membrane Miao et al., 2005
Cyclosporine A Cyclic peptide Tolypocladium inflatum Immunosuppressant /lower the activity of
T cells
Murthy et al., 1999
Actinomycin D Polypeptide Streptomyces sp. Antitumor/inhibit transcription Waksman and Woodruff, 1940
Romidepsin Depsipeptide Chromobacterium violaceum Antitumor/Histone deacetylase inhibitor Ueda et al., 1994
TABLE 2 | Sponge secondary metabolites that are FDA-approved agents in clinical trial (Mayer et al., 2010; Newman and Cragg, 2016).
Compound Biosynthetic class of agent Source Disease/molecular target Clinical status
Cytarabine (Ara-C) Nucleoside Cryptotethya crypta Cancer/DNA polymerase FDA approved
Vidarabine (Ara-A) Nucleoside C. crypta Antiviral viral/DNA polymerase I FDA approved
Eribulin mesylate (E7389) Complex polyketide Lissodendoryx sp. Cancer/microtubules FDA approved
Hemiasterlin derivative (E7974) Modified linear tripeptide (NRPS-PKS) Cymbastella sp. Cancer/microtubules Phase I
Discodermolide Polyketide Discodermia dissolute Cancer/microtubules Phase I
Bengamide derivative (LAF389) Mixed PKS/NRP Jaspis sp. Cancer/methionine
aminopeptidases
Phase I
Spongistatin 1 Macrocyclic lactone polyether Hyrtios erecta Cancer/microtubules Preclinical
Manoalide Sesterterpene Luffariella variabilis Inflammation/inhibition of
Phospholipase A2
Preclinical
Salicylhalimides A Polyketide Haliclona sp. Cancer/microtubules Preclinical
Laulimalide Polyketide Cacospongia mycofijiensis Cancer/microtubules Preclinical
Peloruside A Polyketide Mycale hentscheli Cancer/microtubules Preclinical
et al., 2002; Olson and McCarthy, 2005). However, fungi
and microalgae also symbiotically inhabit sponges. It has
been recognized that one host sponge can possess diverse
symbionts. For example, unicellular heterotrophic bacteria,
unicellular cyanobacteria, and filamentous heterotrophic
bacteria all grow together in sponge Theonella swinhoei
(Bewley et al., 1996). Likewise, a sponge belonging to Aplysina
includes heterogeneous bacteria Bacillus sp., Micrococcus sp.,
Arthrobacter sp., Vibrio sp., Pseudoalteromonas sp., and so on
(Hentschel et al., 2001). Sponge Rhopaloeides odorabile has
β-Proteobacteria, γ -Proteobacteria, Cytophaga, Actinobacteria,
and green sulfur bacteria (Webster et al., 2001). Besides this,
species-specific symbiotic relationship has also been observed.
For example, sponge T. swinhoei and δ-proteobacteria have
shown a specific association with each other (Schmidt et al.,
2000). A species of α-proteobacteria dominates in sponge R.
odorabile over various habitats but is not detected from seawater,
which strongly suggests that the symbiont is species specific
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(Lee Y. K. et al., 2001). On the other hand, one symbiont
occurs commonly in various sponges from different regions
indicating its wide host range (Wilkinson et al., 1981). For
example, cyanobacteria Aphanocapsa sp., Phormidium sp.,
or Oscillatoria spongeliae are found in numerous sponges
(Wilkinson, 1978). Symbiotic associations between sponges
and marine microorganisms might be involved in nutrient
acquisition, stabilization of sponge skeleton, processing of
metabolic waste, and secondary metabolite synthesis. It is
assumed that symbiotic marine microorganisms harbored by
sponges are the original producers of some of these bioactive
compounds (Newman and Hill, 2006). For example, antibiotic
polybrominated biphenyl ether isolated from the sponge
Dysidea herbacea (Demospongiae) are actually produced
by endosymbiotic cyanobacterium O. spongeliae (Unson
et al., 1994). A symbiotic bacterium Micrococcus sp. produces
diketopiperazines previously ascribed to the host sponge Tedania
ignis (Stierle et al., 1988). Another symbiotic bacterium Vibrio
sp. produces brominated biphenyl ethers formerly attributed to
the host sponge Dysidea sp. (Elyakov et al., 1991). Symbiotic
bacterium Vibrio sp. produces an anti-Bacillus peptide andrimid
that was found in the sponge Hyatella sp. extract (Oclarit
et al., 1994). Antimicrobial activity is detected in Micrococcus
luteus isolated from the sponge Xestospongia sp. (Bultel-Poncé
et al., 1998). Antimicrobial compounds such as quinolones
and phosphatidyl glyceride are isolated from a Pseudomonas
sp. collected at the surface of the sponge Homophymia sp.
(Bultel-Poncé et al., 1999). However, the mutual mechanism
between sponge and its microbial associate, in metabolite
production, is not well-understood. Thus, it is extremely relevant
to highlight the therapeutic potential of various secondary
metabolites synthesized by the microbial flora inhabiting
sponges. This is because they open up the possibility of providing
a continuous supply of the biologically active compounds
by laboratory cultivation of the producer (Thomas et al.,
2010).
Tunicates include a wide variety of invertebrates that are
classified within the Phylum chordata based on presence of a
larval notochord during early development. Tunicates contains
about 2150 described species that are divided into 4 classes:
Ascidiacea (Aplousoobranchia, Phlebobranchia, Stolidobranchia)
Thaliacea (Pyrosomida, Doliolida, Salpida), Appendicularia
(Larvacea), and Sorberacea (Ruppert and Fox, 2004). Amongst
these, Ascidacea (commonly known as the ascidians) are highly
studied due to their biologically active metabolites that serve as
antineoplastic agents. Geranyl hydroquinone was first ascidian
metabolite isolated from Aplidium sp. which displayed chemo
protective activity against some forms of leukemia, rous sarcoma,
andmammary carcinoma in test animals (Fenical, 1976) (Menna,
2009). Since then, ascidians are known as the source of numerous
marine natural products. The biologically active metabolites
originated from tunicates which are approved by FDA or in
clinical trials along with their biological properties are given in
Table 3.
To date, significant biological activities, such as antimicrobial,
anticancer, neurotoxic, antiprotozoal and their associated cellular
targets have been reported for several NRPs from the marine
sponges and tunicates. These NRPs have unique structures as
compared with those from other sources. It is this attribute
that makes marine sponge- and tunicate-derived NRPs highly
attractive as potential drug and molecular probes. In this review,
we survey the discoveries of NRPs derived from marine sponges
and tunicates, which have shown in vivo efficacy or potent in
vitro activity against various human diseases. Our objective is to
highlight NRPs that have the greatest potential to be clinically
useful. The details of sponge- and tunicate-derived NRPs along
with biological properties is given Table 4.
ANTICANCER NRPs FROM MARINE
SPONGES AND TUNICATES (FIGURES 1–6)
Sponge Theonella aff. mirabilis was the source of linear penta
peptide Miraziridine A (1), which showed inhibitory activity
on cathepsin B with an IC50 value of 1.4µg/mL (Nakao et al.,
2000). Two cyclic hexapeptides, Haligramides A (2) and B (3),
were isolated from an aqueous extract of the sponge H. nigra.
Both compounds exhibited cytotoxicity against various cell lines.
Haligramide A exhibited cytotoxicity against A-549, HCT-15, SF-
539, SNB-19 cell line with IC50 values of 5.17, 15.62, 9.00, and
9.08 µg/mL, respectively. Haligramide B, was found to be more
active than Haligramide A against A-549, HCT-15, SF-539, SNB-
19 cell line with IC50 values of 3.89, 8.82, 5.01, and 6.56µg/mL,
respectively (Rashid et al., 2000).
A cyclic peptide, Prepatellamide A (4) was isolated from
the cytotoxic extracts of L. patella. The crude extract of this
ascidian showed cytotoxicity against P388 murine leukemia
cell lines with IC50 = ∼5µg/mL (Fu et al., 2000). Naturally
occurring depsipeptides, Tamandarins A and B (5 and 6)
were discovered from a Brazilian ascidian of the family
Didemnidae and were cytotoxic against various human cancer
cell lines including pancreatic carcinoma BX-PC3, IC50 = 1.79,
TABLE 3 | Tunicate secondary metabolites that are FDA-approved agents or in clinical trial (Mayer et al., 2010; Newman and Cragg, 2016).
Compound Biosynthetic class of agent Source Disease/molecular target area Clinical status
Trabectedin (ET-743) (EU registered only) NRPS-derived alkaloid Ecteinascidia turbinata Cancer/minor groove of DNA FDA approved
Plitidepsin (Aplidine) Cyclic depsipeptide Aplidium albicans Cancer/Rac1 and JNK activation Phase III
Trabectedin analog (PM01183) NRPS alkaloid E. turbinata Cancer/minor groove of DNA,
nucleotide excision repair
Phase I
Vitilevuamide NRPS Didemnum cuculiferum and
Polysyncranton lithostrotum
Cancer/microtubules Preclinical
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FIGURE 1 | Structures of anticancer non-ribosomal peptides (1–14).
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FIGURE 2 | Structures of anticancer non-ribosomal peptides (15–26).
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FIGURE 3 | Structures of anticancer non-ribosomal peptides (27–33).
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FIGURE 4 | Structures of anticancer non-ribosomal peptides (34–42).
2.00µg/mL, prostatic cancer DU-145, IC50 = 1.36, 1.53 µg /mL,
head and neck carcinoma UMSCC10b, IC50 = 0.99, 1.7 6 µg/mL,
respectively (Vervoort et al., 2000). Microscleroderma sp. from
Palau gave 4 new cyclic peptides, Microsclerodermins F–I (7–10),
all of which inhibited the growth of C. albicans with MIC value
of 1.5, 3, 12, and 25µg per disk, respectively, and also showed
cytotoxicity against the HCT-116 cell line with IC50 value of 1.8,
2.4, 1.0, and 1.1 µg/mL, respectively (Qureshi et al., 2000).
A histidine-containing proline-rich cyclic heptapeptide,
Wainunuamide (11), was isolated from the Fijian marine sponge
S. aurantium. Compound (11) exhibited weak cytotoxic activity
against A2780 ovarian tumor and K562 leukemia cancer cells
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FIGURE 5 | Structures of anticancer non-ribosomal peptides (43–60).
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FIGURE 6 | Structures of anticancer non-ribosomal peptides (61–69).
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with ID50 of 19.15 and 18.36 µg/mL, respectively (Tabudravu
et al., 2001). The Australian marine sponge L. microraphis was
the source of a bioactive cyclic heptapeptide, Leucamide A
(12). Compound (12) inhibited the growth of the 3 tumor cell
lines HM02 (gastric, GI50 = 5.2 µg/mL), HepG2 (liver, GI50
= 5.9µg/mL), and Huh7 (liver, GI50 = 5.1 µg/mL) (Kehraus
et al., 2002). The Fijian collection of marine sponge S. aurantium
gave a proline-rich cyclic octapeptide, Axinellin C (13) (cyclo
[Thr1-Val2-Pro3-Trp4-Pro5-Phe6-Pro7-Leu8]). Axinellin C
displayed weak cytotoxicity against A2780 ovarian tumor and
K562 leukemia cancer cells with ID50s of 13.17 and 4.46mg/mL,
respectively (Tabudravu et al., 2002). The crude extract of a
marine sponge Cymbastela sp. (Papua New Guinea) gave a
cytotoxic peptide Milnamide D (14). Milnamide D was found
to exhibit cytotoxicity against HCT-116 at IC50 value of 66
nM and inhibition of tubulin polymerization at IC50 of 16 µM
(Chevallier et al., 2003).
Investigation of marine sponge C. olemda yielded 3 new
Kapakahines E−G (15–17). Only kapakahines E was found to
display moderate cytotoxicity against P388 murine leukemia cells
at IC50 of 5.0 µg/mL (Nakao et al., 2003). Two novel cyclic
hexapeptides, Didmolamides A-B (18 and 19) were isolated
from ascidian D. molle (Madagascar). Both peptides showed
mild cytotoxicity against tumor cell lines (Lung—A549, Colon—
HT29, and Skin—MEL28) with IC50 values of 10–20 µg/mL
(Rudi et al., 2003). The Philippines ascidian L. bistratum was
the source of 6 cyclic hexapeptides, Bistratamides E-J (20–25)
which showedweak tomoderate activity against the human colon
tumor (HCT-116) cell line (IC50’s: 3, 7.9; 4, 28; 5, 5; 6, 1.7; 7, 9;
8, 1 µg/mL, respectively) (Perez and Faulkner, 2003). Milnamide
C (26) was isolated from Auletta sp., which showed significant
activity againstMDA-MB-435 breast cancer cells with IC50 values
of 3.2× 10−1 µg/mL (Sonnenschein et al., 2004).
Scleritodermin A (27), a new cyclic peptide, was isolated from
the Lithistid Sponge S. nodosum. Scleritodermin A, inhibited
tubulin polymerization and demonstrated significant in vitro
cytotoxicity against a panel of human tumor cell lines (IC50
< 2 µM), including colon (HCT116), ovarian (A2780), and
breast carcinoma cell lines SKBR3 (Schmidt et al., 2004).
Microcionamides A (28) and B (29) were isolated from the
Philippine marine sponge Clathria (Thalysias) abietina. Both
compounds displayed significant cytotoxicity toward human
breast tumor cell lines MCF-7 and SKBR-3 with IC50 of 125 and
98 nM for compound (28) and 177 and 172 nM for compound
(29), respectively (Davis et al., 2004). Methanol extract of an
Indonesian marine sponge Haliclona sp. gave a linear peptide
Kendarimide A (30) which reversed P-glycoprotein-mediated
multi-drug resistance in mammalian cells (Aoki et al., 2004).
Cycloheptapeptide, Phakellistatin 14 (31), was isolated
from Phakellia sp., (Chuuk, Federated States of Micronesia).
Compound (31) exhibited cytotoxicity against the murine
lymphocytic leukemia P388 cell line at ED50 of 5 µg/mL (Pettit
and Tan, 2005). The marine sponge T. swinhoei was found
to produce highly cytotoxic polypeptides Polytheonamides A
and B (32–33) with 48 amino acid residues. Both compounds
were found to be cytotoxic against P388 murine leukemia cells
with IC50 values of 78, 68 pg/mL, respectively (Hamada et al.,
2005). Two diastereomeric tricyclic peptides Neopetrosiamdes
A (34) and B (35) have been isolated from the marine
sponge Neopetrosia sp. collected in Papua New Guinea. These
peptides inhibited amoeboid invasion of human tumor cells
at 6 µg/mL (Williams et al., 2005). Six new depsipeptides,
Seragamides A–F (36–41) were isolated from sponge S. japonicas
(Okinawan). Except seragamide F, all seragamides have showed
multinuclei formation in NBT-T2 cells at 0.01, 0.02, 0.01, 0.01,
and 0.04mg/mL, respectively. Compound (36) also promotes
the polymerization of G-actin and stabilizes F-actin filaments
(Tanaka et al., 2006). Theonella swinhoei from Papua New
Guinea gave a cyclic depsipeptide, Theopapuamide (42). This
peptide contains several unusual amino acid residues such
as β-methoxyasparagine, 4-amino-5-methyl-2, 3, 5-trihydroxy-
hexanoic acid, and also contains an amide linked fatty acid
moiety, 3-hydroxy-2, 4, 6-trimethyl-octanoic acid (Htoa) with
cytotoxicity against CEM-TART (EC50 = 0.5 µM) and HCT-116
(EC50 = 0.9 µM) cell lines (Ratnayake et al., 2006).
Azumamide A-E (43–47) carboxylic acid containing histone
deacetylase (HDAC) inhibitor cyclotetrapeptides were recovered
from the sponge M. izuensis. Only compound (47) displayed
human histone deacetylase inhibitory activity (Maulucci et al.,
2007). An Indonesian sponge C. aerizusa gave a new cyclic
peptide named Callyaerin G (48)with cytotoxicity against mouse
lymphoma cell line (L5178Y) and HeLa cells with ED50(s) of
0.53 and 5.4 ug/mL, respectively (Ibrahim et al., 2008). The
Papua New Guinea marine sponge Stylotella sp. was found to
produce a new proline-rich cyclodecapeptide, Stylopeptide 2 (49)
which inhibited the growth of BT-549 and HS 578T 2 breast
cancer cell lines by 77 and 56%, respectively (Brennan et al.,
2008). Bioactive lipopeptides Ciliatamides A-C (50–52) were
isolated from the deep-sea sponge A. ciliate. Ciliatamides A-
B have showed anti-leishmanial activity at 10 µg/mL with 50
and 45.5% growth inhibition, respectively. Ciliatamides A-C also
inhibited growth of HeLa cells with IC50 values of 50, 4.5, and 50
µg/mL, respectively (Nakao et al., 2008).
The marine ascidian Diazona sp. (Indonesia) gave 3 new
macrocyclic peptides, Diazonamides C–E (53–55). All the
isolated peptides displayed moderate cytotoxicity against a panel
of 3 human tumor cell lines (IC50’s: A549 = 2.2, 2.9, 8.0 µg/mL;
HT29 = 1.8, 2.9, 5.2 µg/mL; MDA-MB-231 = 2.2, 3.1, 9.0
µg/mL) (Fernández et al., 2008). Dominican marine sponge E.
laughlini gave 2 cyclic heptapeptides, Rolloamides A (56) and
B (57). Rolloamide A displayed significant growth suppression
against several cancer cells (prostate, breast, ovarian, glioma, and
renal) with IC50’s of 0.4–5.8 µM (Williams et al., 2009). Proline-
containing cycloheptapeptide, Euryjanicin A (58) was extracted
from the marine sponge P. laughlini (Vicente et al., 2009).
Bioassay guided extraction of the sponge C. aerizusa (Ambon,
Indonesia) revealed 7 new cytotoxic cyclic peptides Callyaerins
A–F (59–64) and H (65). All peptides have showed cytotoxicity,
however, callyaerins E and H exhibited strong activity against the
L5178Y lymphoma cell line with ED50 values of 0.39 and 0.48
µM, respectively (Ibrahim et al., 2010).
An undescribed sponge of the genus Melophlus sp.
(Karumolum, Russell Is., Solomon Is.) yielded 2 depsipeptides,
Papuamides E (66) and F (67), which were cytotoxic against
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brine shrimp with LD50 values between 92 and 106 µg/mL
(Prasad et al., 2011). A proline-rich octapeptide Stylissamide
X (68) isolated from an Indonesian marine sponge of Stylissa
sp. inhibited HeLa cells in the concentration range 0.1–10 µM
through wound-healing assay (Arai et al., 2012). The marine
sponge C. gombawuiensis collected from Korean waters gave a
disulphide-linked hexapeptide, Gombamide A (69). Gombamide
A showed weak cytotoxic activity against the K562 and A549 cell
lines with LC50 values of 6.9 and 7.1 µM, respectively, as well as
moderate inhibitory activity against Na+/K+-ATPase with an
LC50 value of 17.8 µM (Woo et al., 2013).
ANTI-HIV AGENTS (FIGURES 7, 8)
The marine sponge S. microspinosa was the source of a cyclic
depsipeptide Microspinosamide (70), inhibited HIV-1 infection
with an EC50 value of approximately 0.2 µg/mL (Rashid et al.,
2001). A Papua New Guinea collection of the marine sponge N.
huxleyi has been shown to produce a new HIV-inhibitory cyclic
depsipeptide, Neamphamide A (71). Neamphamide A displayed
potent cytoprotective activity against HIV-1 infection with EC50
value ∼28 nM (Oku et al., 2004). Four cyclic depsipeptides,
Mirabamides A–D (72–75), were isolated from the marine
sponge S. mirabilis. Mirabamides A, C and D inhibited HIV-
1 fusion (Mirabamides A IC50 values between 40 and 140 nM:
Mirabamides C IC50 values between 140 nM and 1.3 µM: and
Mirabamides D IC50 values between 190 nM and 3.9 µM).
Mirabamides A–C also inhibited the growth of B. subtilis and C.
albicans at 1–5 µg/disk (Plaza et al., 2007).
The marine sponge Homophymia sp. was the source of
an anti-HIV cyclodepsipeptide, Homophymine A (76). This
peptide inhibited the infection of HIV-1 in PBMC cell line with
an IC50 of 75 nM (Zampella et al., 2008). Six depsipeptides
Celebesides A-C (77–79) and Theopapuamides B-D (80–
82) were isolated from an Indonesian sponge S. mirabilis.
Compound (77) neutralized HIV-1 with an IC50 value of 1.9
± 0.4 µg/mL, while the non-phosphorylated analog Celebeside
C was inactive at concentrations as high as 50 µg/mL.
Theopapuamides A-C displayed cytotoxicity against human
colon carcinoma (HCT-116) cells with IC50 values between 2.1
and 4.0 µg/mL, and antifungal activity against wild type and
amphotericin B-resistant strains of C. albicans at 1–5 µg/disk
(Plaza et al., 2008). The deep-water specimens of T. swinhoei
and Theonella cupola (Mutremdiu Reef, Palau) gave sulphated
cyclic depsipeptide, Mutremdamide A (83) and 6 N-methylated
peptides Koshikamides C–H (84–89). Cyclic koshikamides F and
H inhibited HIV-1 entry at IC50 values of 2.3 and 5.5 µM,
respectively, while their linear counterparts were inactive (Plaza
et al., 2010).
ANTI-INFLAMMATORY NRPs (FIGURE 9)
Marine sponge S. symbiotica collected from Biaro Island,
Indonesia, alongwith its symbiont marine red alga (Rhodophyta)
Ceratodictyon spongiosum gave thiazole-containing
cyclic heptapeptide, Ceratospongamide (90). Compound
(90) consists of two l-phenylalanine residues, one
(l-isoleucine)-l-methyloxazoline residue, one l-proline residue,
and one (l-proline) thiazole residue. The trans-isomer of
ceratospongamide exhibits potent inhibition of sPLA2 expression
in a cell-based model for anti-inflammation at ED50 32 nM (Tan
et al., 2000). Two cyclic depsipeptides, Halipeptins A and
B (91,92) were obtained from marine sponge Haliclona sp.
Only halipeptins A displayed in vivo potent anti-inflammatory
activity (mice at the dose of 300 µg/kg [i.p.]) (Randazzo et al.,
2001). A Solomon Lithistid sponge T. swinhoei was the source
of 2 new cyclopeptides Perthamides C and D with potent
anti-inflammatory (93,94) (Festa et al., 2009). Cyclic peptides,
Solomonamides A and B (95,96), were separated out from
the marine sponge T. swinhoei; however, only compound (86)
showed anti-inflammatory activity (Festa et al., 2011). The
marine sponge S. massa produced a cyclic peptide Stylissatin A
(97) that inhibited nitric oxide production in LPS-stimulated
murine macrophage RAW264.7 cells with an IC50 value of 87
µM (Kita et al., 2013).
ANTIMICROBIAL AGENTS (FIGURE 10)
The solitary tunicate, H. aurantium, was the source of a
novel antimicrobial peptide Dicynthaurin (98) (Lee I. H. et al.,
2001). An antibacterial depsipeptide, Nagahamide A (99), was
discovered from the marine sponge T. swinhoei (Okada et al.,
2002). An antimicrobial octapeptide Plicatamide (100) was
isolated from S. plicata (Tincu et al., 2003). The marine sponge
Latrunculia sp., (Vanuatu Islands) was the source of four new
antifungal peptides, Callipeltins F–I (101–104). Callipeltins F–I
inhibit the growth of C. albicans (ATCC24433) with a MIC value
of 10−4 M (Sepe et al., 2006). Four new peptides, Callipeltins J–
M (105–108), were isolated from the marine sponge Latrunculia
sp. However, only Callipeltins J and K inhibited the growth of C.
albicanswithMIC values of ca. 4−10 M(D’Auria et al., 2007). Two
new linear tetrapeptides, Citronamides A (109) and B (110), were
isolated from the Australian sponge C. astra. Only citronamides
A showed moderate antifungal activity against Saccharomyces
cerevisiae at MIC value of 8 µg/mL (Carroll et al., 2009).
MISCELLANEOUS (FIGURE 11)
A cyclic tripeptide Renieramide (111) was isolated from Vanuatu
collection of sponge Reniera sp. that showed immunomodulating
activity in preliminary tests (Ciasullo et al., 2002). Two
nematocidal depsipeptides, Phoriospongin A and B (112
and 113), were isolated from Australian marine sponges
Phoriospongia sp. and C. bilamellata. Both compounds have
displayed significant nematocidal activity against H. contortus
(LD99 = 100, 194µg/mL, respectively) (Capon et al., 2002).
BIOLOGICAL ASPECTS, CHALLENGES,
AND FUTURE PERSPECTIVES
Like their structural diversity, metabolites produced frommarine
sponges and tunicates bind to a variety of cellular targets to
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FIGURE 7 | Structures of non-ribosomal peptides with anti-HIV activity (70–82).
elicit their effects. Numerous articles published in recent years
highlighting the significance of these metabolites in disease
control, the details of their biological significance frommolecular
recognition perspective have been rather scarce. Although some
promising leads have been obtained, the discovery of their
cellular targets, molecular interactions, and adverse effects are
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FIGURE 8 | Structures of non-ribosomal peptides with anti-HIV activity (83–89).
lacking. In cases where the therapeutic potential has been
reported, details of a proper screening approach to identify
nucleic acid or protein targets are missing. However, some
established metabolites from these sources (see Tables 1, 2)
and their derivatives have been examined extensively and their
molecular targets are varied. One of the earliest examples in
Frontiers in Pharmacology | www.frontiersin.org 15 October 2016 | Volume 7 | Article 333
Agrawal et al. NRPs Marine Sponge, Tunicates, Pharmacological
FIGURE 9 | Structures of non-ribosomal peptides with anti-inflammatory activity (90–97).
this class is FDA-approved drug Ara-C (cytarabine), which is
known to elicit anticancer properties by inhibiting the functions
of DNA polymerase (Furth and Cohen, 1968), which ultimately
results in stalling DNA synthesis. Another FDA approved related
compound Ara-A(vidarabine), which is known to have antiviral
properties (active against herpes simplex and varicella zoster
viruses), targets viral DNA polymerase (Chadwick et al., 1978)
by functioning as mimic of natural nucleotides. Both Ara-C and
Ara-A resemble natural cytidine and adenine nucleosides where
the structural differences are in the sugar components of the
two (arabinose vs. deoxyribose). The natural nucleoside mimics
Ara-A and Ara-C are easily phosphorylated as their triphosphate
derivatives by kinases and act as terminators of DNA synthesis.
Ara-A is also known to impede 3′-end processing of pre-mRNAs
by inhibiting cleavage and polyadenylation (Ghoshal and Jacob,
1991; Rose and Jacob, 1978).
Several other molecules that are either FDA approved or in
early stages of clinical trials have been identified as anticancer
agents with microtubules as their primary molecular targets.
The predominance of natural metabolites being microtubule
binding agents has been hypothesized as evolutionary response to
predation by plants and animals (Dumontet and Jordan, 2010).
Some of these molecules, such as discodermolide, are among
the first non-taxane stabilizers of microtubules (Mooberry et al.,
2004). The microtubule stabilizers act by enhancing microtubule
polymerization at high concentrations. Discodermolide has been
known to bind to tubulin dimers in a stoichiometric ratio.
Competitive binding experiments have shown that it blocks taxol
binding and is a much stronger binder of microtubules than taxol
(Kowalski et al., 1997). The microtubule binding of Tau proteins
is interfered by discodermolide (Kar et al., 2003). Similarly,
laulimalide showed properties very similar to paclitaxel where
it helped in enhancing tubulin assembly (Gapud et al., 2004).
However, laulimalide modulation of microtubule assembly in
C. elegans is dose dependent where it stabilization effects were
observed only at concentrations higher than 100 nM (Bajaj and
Srayko, 2013).
The antiviral effect of homophymine A has been established
by measuring the reverse transcriptase activity in HIV-infected
primary peripheral blood mononuclear cells (Zampella et al.,
2008). The reverse transcriptase activity is exhibited by 2
classes of molecules: one that directly competes with natural
nucleotide triphosphates and the other that either directly blocks
the catalytic reactions or by allosteric binding that leads to
structural changes in the viral enzyme. Since homophymine A
lacks structural features to act as mimics of natural nucleotide
triphosphates, it is likely to impede the catalytic activity of the
enzyme by direct binding.
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FIGURE 10 | Structures of antimicrobial non-ribosomal peptides (98–110).
A tunicate-derived metabolite trabectedin (ET-743) uses DNA
binding to exert its anticancer properties. Trabectin binds to the
GC rich regions in the B-DNA where it uses its carbolinamine
moiety to form adduct with the exocylic amine (N-2) of guanine
(Pommier et al., 1996) and covers 3 base pairs during this process
(Marco et al., 2006). Unlike B-DNA minor groove binders, such
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FIGURE 11 | Structures of non-ribosomal peptides with (111–113).
as Hoechst 33258, which binds snugly along the minor groove
curvature with high-affinity (Haq et al., 1997), trabectedin only
uses part of its structure to make necessary contacts for the
antitumor action (D’Incalci and Galmarini, 2010).
Despite these advances in determining the mode of their
binding, a large number of recently discovered metabolites
are still not explored to assess it functional capabilities. In
the past, well-known anti-retroviral drug zidovudine, which
was initially thought to be functionally inert, turned out
as excellent therapeutic agent. Such discoveries are possible
only when a rational screening design is aimed to asses
it full potential as a drug. For example, compounds that
have structural regions favorable for protein binding should
be screened against all potential protein targets. Similarly,
compounds that show preference toward nucleic acid binding
should be screened using assays such as competition dialysis
that establish a preferential nucleic acid target. Such approaches
not only determine the best target for a particular compound
but also shed light to its secondary targets, which may be
helpful in dealing with toxicity issues. Current target design
of marine and tunicate metabolites clearly need to take these
approaches.
Some of the metabolites that have weaker binding to
a target or have poor bioavailability can be improved by
nano-encapsulation techniques. Additionally, DNA binding
metabolites can be chemically modified to enhance their affinity
using multi-recognition of the target (Willis and Arya, 2010),
which has led to remarkable enhancement in the affinity of
double,(Arya et al., 2003), triple (Arya and Willis, 2003),
and four-stranded DNA helical structures (Ranjan et al.,
2013).
CONCLUSION
Extreme environment of the ocean plays a vital role in exploring
and studying marine bio-resources and their bio-actives. The
large biodiversity of the sea serves as a huge resource for
developing potential drugs with promising pharmacological
activities. The significance of marine-derived secondary
metabolites has recently been highlighted by introduction of
Prialt and Yondelis to the market. In the past three decades,
numerous NRPs with unique chemical structures and varied
biological activities have been discovered from marine sponges
and tunicates as described in this. Some of these exhibit strong
potential to be developed as a new drug. However, none of the
NRPs highlighted in this review have been successfully marketed
as therapeutics. To translate bioactivity of these important
metabolites into therapeutically significant outcomes, it is
crucial to further unravel their modes of action and measure
their toxicity. Since the majority of these studies have been
focused on in vitro bioassays and elucidation of the chemical
structures only, a complete examination of their biological
target selectivity is required. Nevertheless, large-scale production
of these NRPs for clinical use is a real challenge. Therefore,
environmentally sound and economically feasible alternatives
are required. To counter these challenges, many strategies have
been established.
Chemical synthesis of NRPs is among the first strategies
to be used. However, the structural complexity limits its
chemical synthesis and has resulted in only a few successful
achievements (e.g., analgesic drug ziconotide; Olivera, 2000). A
second strategy uses screening the pharmacological significance
of NRPs and subsequently attempting to define the critical
pharmacophore that can result in practical drugs based
on a marine prototype via chemical synthesis, degradation,
modification, or a combination of these. Aquaculture of the
source organisms has also been used to secure a sustainable
supply of active compounds. However, in most cases, the
biomass currently generated is still far from the requirement
from an industrial perspective (Mendola, 2000). Identification
and large-scale culturing of true producers that are known to
thrive within the tissues of marine invertebrates (sponge or
tunicate) is an intriguing strategy. However, to date only 5%
or less of the symbiotic microbes present in marine specimens
can be cultivated under standard conditions. Consequently,
molecular approaches such as transfer of biosynthetic gene
clusters to a vector suitable for large-scale fermentation
could be used to avoid obstacles in culturing symbiotic
bacteria. Enzyme technology and solid-phase peptide synthesis
offer particularly promising alternatives to generate variety
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of unique peptides using native peptide as a template.
Besides, combinations of chemical synthesis and biosynthetic
technologies have potential to accelerate the discovery of novel
drugs derived from sponge and their microbial association in
future.
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